Ironwood Pharmaceuticals Stock Analysis

Ironwood Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.01. Ironwood Pharmaceuticals last dividend was issued on the 2nd of April 1970. The entity had 1194:1000 split on the 2nd of April 2019. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. To learn more about Ironwood Pharmaceuticals call the company at 617 621 7722 or check out https://www.ironwoodpharma.com.

Ironwood Pharmaceuticals Investment Alerts

Ironwood Pharmaceuticals Upcoming and Recent Events

Ironwood Largest EPS Surprises

View All Earnings Estimates

Ironwood Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Ironwood Pharmaceuticals Thematic Classifications

Ironwood Stock Institutional Investors

Note, although Ironwood Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ironwood Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 563.3 M.

Ironwood Profitablity

The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.28.

Management Efficiency

Ironwood Pharmaceuticals has return on total asset (ROA) of 0.1305 % which means that it generated a profit of $0.1305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.

Technical Drivers

As of the 22nd of November, Ironwood Pharmaceuticals retains the Standard Deviation of 4.42, risk adjusted performance of (0.05), and Market Risk Adjusted Performance of (0.12). Ironwood Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ironwood Pharmaceuticals information ratio and skewness to decide if Ironwood Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 3.34 per share. Given that Ironwood Pharmaceuticals has information ratio of (0.10), we strongly advise you to confirm Ironwood Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.

Ironwood Pharmaceuticals Price Movement Analysis

Ironwood Pharmaceuticals Insider Trading Activities

Ironwood Pharmaceuticals Outstanding Bonds

Ironwood Pharmaceuticals Predictive Daily Indicators

Ironwood Pharmaceuticals Corporate Filings

Ironwood Pharmaceuticals Forecast Models

Ironwood Pharmaceuticals' time-series forecasting models are one of many Ironwood Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ironwood Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ironwood Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ironwood shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ironwood Pharmaceuticals. By using and applying Ironwood Stock analysis, traders can create a robust methodology for identifying Ironwood entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ironwood analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ironwood analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Ironwood Pharmaceuticals stock analysis indicators help investors evaluate how Ironwood Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ironwood Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ironwood Pharmaceuticals stock analysis, traders can identify Ironwood Pharmaceuticals position entry and exit signals to maximize returns.

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.